ALK CEO eyes higher growth rates - in 2017
The new products will not start selling for real in 2016, and the expectations so far land below analysts’. Jens Bager, CEO of ALK-Abelló looks to 2017, where one drug in particular will drive future growth.
BY BENJAMIN WERNER CHRISTENSEN
The Danish allergy group finished the third quarter 2015 in weaker form than expected, and the company’s preliminary projections for 2016 do not seem to indicate that the coming year will boom and boost the revenue to new heights.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK rival in clinical setback
For abonnenter
ALK to close Swiss business unit
For abonnenter
ALK heading to FDA with dust mite vaccine
For abonnenter
